Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $49.7778.

A number of research analysts recently commented on CLDX shares. Barclays boosted their price target on Celldex Therapeutics from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Monday, April 20th. Wells Fargo & Company boosted their target price on Celldex Therapeutics from $38.00 to $54.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 13th. The Goldman Sachs Group boosted their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. Finally, Stifel Nicolaus reissued a “buy” rating and set a $68.00 target price (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Segall Bryant & Hamill LLC raised its stake in Celldex Therapeutics by 36.3% during the third quarter. Segall Bryant & Hamill LLC now owns 528,597 shares of the biopharmaceutical company’s stock worth $13,675,000 after acquiring an additional 140,709 shares in the last quarter. American Century Companies Inc. raised its stake in Celldex Therapeutics by 4.6% during the third quarter. American Century Companies Inc. now owns 815,560 shares of the biopharmaceutical company’s stock worth $21,099,000 after acquiring an additional 35,575 shares in the last quarter. Propel Bio Management LLC acquired a new position in Celldex Therapeutics during the third quarter worth about $4,010,000. Eventide Asset Management LLC raised its stake in Celldex Therapeutics by 37.1% during the third quarter. Eventide Asset Management LLC now owns 1,859,095 shares of the biopharmaceutical company’s stock worth $48,096,000 after acquiring an additional 502,909 shares in the last quarter. Finally, Braidwell LP bought a new stake in shares of Celldex Therapeutics during the third quarter worth about $15,307,000.

Celldex Therapeutics Stock Down 3.6%

CLDX stock opened at $30.22 on Tuesday. The company has a market cap of $2.37 billion, a PE ratio of -7.09 and a beta of 0.98. The business has a 50-day simple moving average of $31.99 and a 200 day simple moving average of $28.12. Celldex Therapeutics has a 52 week low of $18.55 and a 52 week high of $35.79.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($0.03). The company had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.80 million. On average, analysts anticipate that Celldex Therapeutics will post -4.45 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.